-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Public Health and Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
Connected Intelligence
-
AI & Machine Learning
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Genomics
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
AI & Machine Learning with a healthcare IQ.
Artificial intelligence is accelerating opportunities. Realizing the benefits for healthcare requires the right expertise. Together, we can solve the problems of today, and drive the breakthroughs of tomorrow.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Unlock the power of genomic research.
IQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSBlog
Why Is Forecasting Biosimilar Impact So Difficult?
Jan 08, 2020
Forecasting is challenging enough when you have years of historic data to analyze. But what happens when, like biosimilars, your newly launched product is in a new category with little precedent? Or what if your biologic product is facing incoming biosimilar competition? Forecasters launching today are facing exactly this challenge.
As patents on branded biologics expire, the biosimilars industry is expected to take off. But expectations and reality don’t always meet.
The impact of brand loss of exclusivity for patented biologics through 2023 is estimated to be approximately $95 billion, meaning a big hit for current products. The market is also expected to grow quickly – meaning significant opportunity for new entrants. However, IQVIA data shows that biosimilar uptake has not been easy to predict, with many approved products facing delayed launches or slower than expected uptake. Regulations are also still evolving, with most countries establishing their own rules and pace for biosimilar approval and market access.
All of this makes it difficult to accurately predict demand for new biosimilars, or to understand the impact they will have on soon-to-be-patentless biologics.
The lack of historic data, along with trends which haven’t played out as expected, has resulted in inaccurate commercial forecasts. In some cases, biosimilar manufacturers predicted revenues and sales potential multiple times higher than occurred. This led them to invest substantially more resources than was needed on sales teams and production, eroding margins.
Beyond the Spreadsheet
No matter how skilled your forecasters are, this level of analysis cannot be completed using spreadsheets and intra-company data. To produce an effective strategy for biosimilars, forecasters must be able to look beyond their internal data and model every player, every product, and every regulatory environment to accurately predict a biosimilar’s current and future potential. That requires a sophisticated forecasting platform that can rapidly access and analyze information, adjust results to accommodate uncertainties, and forecast regional and global trends on a real-time basis.
The technology exists today to achieve these goals. Machine Learning (ML) prediction tools can be connected to global healthcare datasets - and supported by subject matter experts who understand the regional differences in approach to biologics - have produced the most accurate forecasts of biologics uptake to date. But such approaches require forecasters to “step outside” their current ecosystem of spreadsheet-based forecasting and integrate new types of forecasting approaches.
Forecasters looking to accommodate the uncertainties of the biosimilar space should look for platforms or approaches to support them in doing the following:
- Build more granular regional models that reflect country-specific biosimilar approaches. Biosimilar forecasts should have access to global healthcare data and the ability to forecast local-to-global results on a real time basis. This will increase accuracy in specific countries, reduce the cycle time to assess portfolio impact, and help teams make more effective investment decisions.
- Model the entire market for an indication, not just your product. Evaluate the impact of market events, and allow tuning of market dynamics, rather than just looking at one product at a time. This more holistic approach to forecasting considers all competitors and market-wide events, as well as a patient funnel for the entire market.
- Explicitly consider and account for different biosimilar scenarios. An effective model should account for multiple biosimilar scenarios reflecting different possible future states because of uncertain and rapidly changing biosimilar dynamics. Making this data visible to management helps senior leadership make more effective tradeoffs even without full information. Modular tools can make it so those scenarios can be adjusted within minutes as new data comes in.
- Be able to interpret key drivers of change, especially around biosimilar erosion or uptake. Sensitivity analysis should allow forecasters to identify those factors where small changes have big impacts. For biosimilars, these factors could include competitor pricing, number of competitors and their approval dates in certain markets, or the extent to which promotion may affect market uptake. And this analysis must include both tornado charts (one-factor-at-a-time) and Monte Carlo (many-factors-at-a-time) analysis to understand the cumulative impact of multiple simultaneous changes in this quickly evolving sector.
Biosimilars hold enormous growth potential -- but biopharmaceutical companies need to figure out how to navigate the marketplace and accurately forecast product demand if they are to maximize benefit. Using the right tools and approaches to forecasting biosimilar impact will be critical to achieving early success and gaining (or retaining) market share within this rapidly growing industry sector.
To learn more about our approach to biosimilar forecasting click here or contact us at ForecastHorizon@iqvia.com